Ceruvia Lifesciences announced an $8 million founder-backed investment on August 3 to complete funding for an integrated Phase 1/2 trial of BOL-148, its proprietary non-hallucinogenic LSD analog, for cluster headache, a condition sometimes called the suicide headache for its severity and limited treatment options. The company plans to file its Clinical Trial Application in Germany this September, enroll its first participants in the fourth quarter, and report Phase 1 topline data in the second quarter of 2027. On its own, this is a legitimate, well-supported entry into an indication this desk has already flagged as having preliminary evidence behind it. What makes it worth a closer look is who is funding it, and what else that person has spent the last several years doing in this same industry.
Who Carey Turnbull is in this field
Turnbull founded Ceruvia in 2017 and remains its Founder and CEO, funding this latest round personally through what the company describes as founder-backed investment. He is also the founder of Freedom to Operate, a nonprofit he established in 2020 specifically to challenge what he has called bad patents on psychedelic compounds, a board member of Usona Institute, a nonprofit that deliberately places its own psilocybin research findings into the public domain as a direct alternative to patenting them, and president of the Heffter Research Institute. Across these roles, Turnbull has been the single most persistent and effective critic of Compass Pathways’ patent strategy in this industry. Freedom to Operate’s challenges forced Compass to withdraw an original 27-claim patent application, then a resubmitted 10-claim version, on grounds that the underlying crystalline psilocybin forms amounted to prior art already established by LSD’s inventor Albert Hofmann decades earlier. FTO went on to file a formal Post-Grant Review petition against Compass’s Polymorph A patents directly, a petition PTAB ultimately denied in 2022, though Turnbull maintained at the time that the ruling’s narrow interpretation of Compass’s claims would still leave generic manufacturers meaningful latitude.
The part that complicates the story
Ceruvia says it holds patents on BOL-148, marketed under the proprietary name NYPRG-101, including a formulation patent. That overlap has already been noted publicly by at least one independent commentator, who observed that Turnbull’s advocacy work and his own company’s patent position exist alongside each other in a way not always visible to readers following his public statements against Compass specifically. This desk is not in a position to adjudicate whether Ceruvia’s patents on BOL-148 are meaningfully different in kind from the claims Freedom to Operate successfully challenged at Compass, a formulation patent on a licensed, decades-old compound is not automatically the same category of claim as a composition-of-matter patent on a crystalline form, and reasonable people in patent law could draw that distinction differently. What can be stated plainly is that both things are true at once: Turnbull has built a substantial public reputation, across three nonprofit roles, specifically around opposing broad patent claims in this industry, and his own for-profit company holds patent protection on its own lead compound.
What BOL-148 has going for it, independent of any of this
The compound itself carries a long history. BOL-148, also known as 2-bromo-LSD, has been administered in clinical and experimental settings since the 1950s. Ceruvia says roughly 300 people have been exposed to it across its research history, and that it holds a patent license from Harvard specifically for its use in cluster headache. An earlier open-label case series in the clinical literature documented a signal: across six patients treated with BOL-148, attack frequency fell, and five experienced remission lasting several weeks to months. Ceruvia’s own positioning is that BOL-148 is designed to preserve the underlying pharmacology’s therapeutic potential without the hallucinogenic experience, a claim this desk treats carefully given how contested the question of whether the subjective psychedelic experience is separable from the treatment effect has been across this entire drug class. This trial, an integrated Phase 1 dose-escalation moving directly into a randomized, placebo-controlled Phase 2 proof-of-concept, is a well-designed test of that specific question in a specific, underserved indication.
Why this belongs in the same conversation as the rest of this desk’s IP coverage
This desk has spent considerable attention this year on the mechanics of psychedelic patent disputes, Compass’s Polymorph A challenges, the ongoing dispute between AtaiBeckley and GH Research over mebufotenin, and the general question of how intellectual property shapes who controls access to this drug class. Turnbull’s dual position, chief antagonist to one company’s patent strategy and patent holder in his own right, is not a contradiction that needs resolving so much as a useful reminder that the “patents versus open access” framing this industry often uses is less a clean binary than most coverage, this desk’s own prior coverage included, tends to suggest. Nearly everyone building a company in this space needs some intellectual property protection to raise the capital a Phase 3 program requires, Turnbull’s own $8 million check included. The actual dividing line worth watching is not whether a company holds patents at all, but how broad those claims are and whether they would block legitimate competition or generic manufacture once a compound is established.
The caveats
This desk has not independently reviewed Ceruvia’s specific patent claims on BOL-148 or NYPRG-101 against the prior-art standard Freedom to Operate has applied to Compass, and nothing here should be read as an allegation that Ceruvia’s patents are improper or overbroad; that would require the same rigorous review this desk has not conducted. BOL-148’s supporting evidence, while genuine, remains an open-label case series from a small patient population, not the randomized, controlled data this new trial is specifically designed to generate. And Turnbull’s public advocacy work through Freedom to Operate and Usona long predates this specific funding announcement; this piece is not suggesting any change in his stated positions, only noting that both roles exist simultaneously and have been reported together by at least one other outlet already.
The frame
An $8 million funding round for a well-supported cluster headache trial would ordinarily be a straightforward, positive story about an underserved indication getting serious investment. It becomes a more interesting one specifically because of who is writing the check and what else that person has spent years doing in this industry’s patent fights. Neither fact diminishes the other. Turnbull’s opposition to Compass’s specific claims may well be entirely correct on the merits, and Ceruvia’s own patent position may be entirely defensible on different grounds. What this desk would want to see, and what none of the coverage of either side of Turnbull’s work has yet supplied, is a direct, specific comparison of what Ceruvia’s BOL-148 patents actually claim against the prior-art standard Freedom to Operate has applied everywhere else. Until that comparison exists, the honest read is that one of this industry’s most vocal patent critics is also, by his own company’s structure, a patent holder, and both facts are simply true.